Skip to content
    LFST
    Earnings call· Jun 2026(Q2 FY26)

    LifeStance Health Group Q2 FY26 earnings call LFST

    Aug 6, 2026 Source

    Executive summary

    LifeStance Q2 FY26 — Exceeds Guidance with Strong Revenue Growth and Margin Expansion

    LifeStance Health delivered another strong quarter, surpassing guidance with robust revenue growth and significant adjusted EBITDA margin expansion, driven by increased clinician productivity and effective payer contracting. The company is strategically investing in technology, specialty services, and geographic expansion via tuck-in acquisitions, while preparing for a new EHR rollout in 2027. Management emphasizes its commitment to clinical outcomes and maintaining constructive payer relationships, positioning for sustained long-term growth despite near-term investment impacts.

    Highlights

    5

    • Revenue grew over 26% to $435 million, exceeding expectations.

    • Adjusted EBITDA increased 94% to $66 million, with margins exceeding 15.2%.

    • Clinician base grew to over 8,500, an 11% increase, with strong productivity (visits per average clinician up 7% YoY).

    • Free cash flow generated $88 million, up from $57 million in the prior year.

    • Full-year guidance raised across all metrics, with revenue midpoint up $45 million and Adjusted EBITDA midpoint up $15 million.

    Concerns

    2

    • Investments in patient acquisition, technology, clinical excellence, and clinician compensation will impact Q3 EBITDA, which is expected to be down sequentially to $49 million to $59 million.

    • The transition to a new EHR planned for 2027 is expected to cause a "short-term blip in productivity" for clinicians.

    Guidance & targets

    10
    CategoryTargetConfidence
    Full Year 2026 Revenue
    $1.685 billion to $1.725 billion
    high materiality
    High
    Full Year 2026 Center Margin
    $570 million to $594 million
    medium materiality
    High
    Full Year 2026 Adjusted EBITDA
    $215 million to $235 million
    high materiality
    High
    Full Year 2026 Stock-Based Compensation
    approximately $60 million to $70 million
    low materiality
    Medium
    Q3 2026 Revenue
    $420 million to $440 million
    medium materiality
    High
    Q3 2026 Center Margin
    $140 million to $152 million
    medium materiality
    High
    Q3 2026 Adjusted EBITDA
    $49 million to $59 million
    medium materiality
    High
    Long-term Adjusted EBITDA Margin
    15% to 20% range
    high materiality
    High
    FY28 Adjusted EBITDA Margin
    mid-teen margins
    high materiality
    High
    Long-term Visit Growth
    low double-digit visit growth year-over-year
    medium materiality
    High

    Operational metrics

    18
    Revenue growth
    26%YoY
    Q2 FY26
    Adjusted EBITDA Margin
    15.2%up over 500 bps YoY
    Q2 FY26
    Clinician base
    8,542up 11% YoY
    Q2 FY26 end

    Added 193 clinicians in Q2.

    Visit volumes
    2.6 millionup 19% YoY
    Q2 FY26

    Driven by clinician productivity and net clinician adds.

    Revenue per visit (TRPV)
    $167up 6% YoY
    Q2 FY26

    Ahead of expectations, driven by payer contracting.

    Visits per average clinician
    7%YoY increase
    Q2 FY26

    Third consecutive quarter of strong increase.

    Center Margin
    $153 millionup 41% YoY
    Q2 FY26

    Ahead of expectations due to revenue beat.

    Cash position
    $226 million
    Q2 FY26 end

    Post $49 million deployment for share repurchases.

    Net long-term debt
    $259 million
    Q2 FY26 end
    Net leverage ratio
    0.2x
    Q2 FY26 end
    Gross leverage ratio
    1.3x
    Q2 FY26 end
    Share repurchase authorization
    $100 millionnew authorization
    announced Q2 FY26

    Approved by Board of Directors.

    Prior share repurchase program deployment
    $97 millionof $100 million authorized capacity
    YTD FY26

    Deployed from initial $100 million program.

    Specialty services revenue growth
    roughly 40%YoY
    FY26

    Expected for this year, higher than core business growth.

    Specialty services revenue
    $50 million
    FY25

    Comprised this amount last year.

    Clinician utilization
    70%
    current

    Of the time clinicians give us.

    Market share of mental health clinician universe
    low to mid-single-digit
    current

    Indicates significant room for growth.

    Payroll and 401(k) match impact on FCF
    roughly $60 million
    Q3 FY26

    Due to favorable timing in Q2, these payments will impact Q3 FCF.

    Industry KPIs

    5
    MetricValueDetails
    Utilization trends70%%
    Same facility volumes2.6 millionvisits
    Payer mix supplemental payments6% YoY%
    Membership covered lives by line8,542clinicians
    Adjusted EPS EBITDA leverage guidance$215 million to $235 millionUSD

    Deals & partnerships

    1
    UndisclosedSmall tuck-in acquisition

    Expands therapy and psychiatry presence in Arizona. Primary intent for M&A is to open up new geographies.

    Risks & headwinds

    3
    Short-term blip in clinician productivity during new EHR rolloutNext year (2027)

    Not quantified, but acknowledged as an impact.

    Mitigation: Working to minimize disruption as much as possible.

    Adjusted EBITDA expected to decline sequentially in Q3 FY26Q3 FY26

    Q3 Adjusted EBITDA guidance of $49 million to $59 million, down from Q2's $66 million.

    Mitigation: Due to planned strategic investments in patient acquisition, technology, clinical excellence, and clinician compensation to support long-term growth.

    Impact of payroll and 401(k) match payments on Q3 FCFQ3 FY26

    Roughly $60 million

    Mitigation: Benefited from favorable timing in Q2, now impacting Q3.

    What to watch in Q3 FY26

    5

    Q3 FY26 Adjusted EBITDA Performance

    Q3 FY26
    Current$66 million (Q2 FY26)
    TargetWithin $49 million to $59 million range

    Why it matters

    To confirm management's ability to balance strategic investments with profitability and meet sequential guidance.

    For the third quarter, we expect revenue of $420 million to $440 million, Center Margin of $140 million to $152 million and adjusted EBITDA of $49 million to $59 million.

    Q&A highlights

    6

    What levers remain to pull on clinician productivity given difficult comps?

    Management stated it's their fourth quarter of strong productivity and they continue to evaluate opportunities. Levers include improving new patient conversion, optimizing clinician schedules, and balancing existing capacity utilization with new clinician adds. They currently utilize about 70% of clinician time.

    “We're utilizing right now about 70% of the time that clinicians give us.”

    asked by Craig Hettenbach · answered by David Bourdon

    2 min read7 chapters

    Detailed Narrative

    01

    Strong Q2 Outperformance and Raised Full-Year Outlook

    LifeStance exceeded all guided metrics for Q2 FY26, delivering over 26% revenue growth to $435 million and adjusted EBITDA margins exceeding 15.2%. This strong performance led to a full-year guidance raise across all metrics, with the revenue midpoint increasing by $45 million and adjusted EBITDA midpoint by $15 million, reflecting confidence in continued momentum.

    02

    Clinician Growth and Productivity

    The company's clinician base expanded to over 8,500, representing 11% year-over-year growth, driven by a compelling value proposition that resonates across various clinician cohorts. Clinician productivity remained strong for the fourth consecutive quarter, with visits per average clinician increasing 7% year-over-year, contributing significantly to visit volume growth of 19%.

    03

    Strategic Investments for Future Growth

    Management plans to make additional investments in the second half of FY26, including patient acquisition and marketing, technology and AI enablement, clinical excellence teams, and enhanced clinician compensation. These investments are reflected in the updated outlook and are aimed at supporting long-term growth objectives, even if they lead to a sequential dip in Q3 EBITDA.

    04

    Specialty Services Expansion and Future Potential

    Specialty services, including neuropsych testing, TMS, and Spravato for treatment-resistant depression, are a key growth driver, expected to grow approximately 40% this year. The company is expanding these services into additional centers and is monitoring the potential for psychedelics, viewing them as a significant future opportunity to improve patient outcomes and contribute to growth and margins.

    05

    EHR Transition and Technology Enablement

    LifeStance is preparing for a transition to a new EHR vendor in 2027, which is expected to be a critical enabler for streamlining operations, enhancing patient and clinician experience, and improving clinical outcomes. The company is also deploying digital, AI-enabled, and workflow automation tools to drive efficiency and improve patient access across various functions.

    06

    Geographic Expansion via Disciplined M&A

    The company sees significant opportunity to increase density in existing markets and expand into new geographies, currently present in only about half of the 150 largest U.S. markets. Small tuck-in acquisitions are the preferred approach for entering new geographies, as demonstrated by a recent acquisition in Arizona, with a growing pipeline of strategic opportunities.

    07

    Focus on Clinical Outcomes and Payer Relationships

    LifeStance continues to emphasize clinical excellence, with recent data showing that at least 75% of patients experienced clinically meaningful improvement in anxiety and depression symptoms across diverse populations. This focus on measurable outcomes is seen as a key differentiator, strengthening partnerships with payers who are increasingly shifting from solely access-based to outcomes-based considerations.

    AI-generated summary of the company’s earnings call. Not investment advice.